New combo therapy shows promise for hard-to-treat cancers
NCT ID NCT05307874
First seen Jan 05, 2026 · Last updated May 16, 2026 · Updated 17 times
Summary
This study tested a new drug combination (ICT01 plus low-dose IL-2) in 56 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to see if the combination is safe and can shrink tumors. The study also added a third drug (pembrolizumab) in later stages to boost effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
IUCT Oncopole Claudius Regaud
Toulouse, France
-
Institute Gustave Roussy
Paris, France
-
The Institute of Cancer Research
Sutton, United Kingdom
-
University Carl Gustav Carus
Dresden, Germany
-
Universitätsklinikum Wuerzburg
Würzburg, Germany
Conditions
Explore the condition pages connected to this study.